EGFR mutation testing practice in advanced non-small cell lung cancer.

Area of Science:

• Oncology
• Molecular Diagnostics

Background:

• Epithelial growth factor receptor (EGFR) gene mutations are critical biomarkers in advanced non-squamous non-small cell lung cancer (NSCLC).
• Current guidelines recommend EGFR mutation testing for eligible NSCLC patients.

Purpose of the Study:

• To assess the current clinical practice of Medical Oncologists in Israel regarding EGFR mutation testing in advanced NSCLC.
• To understand the routine use and timing of EGFR testing in NSCLC patient management.

Main Methods:

• An internet-based survey was distributed to members of the Israeli Society for Clinical Oncology and Radiotherapy.
• The survey targeted oncologists involved in the treatment of lung cancer patients.

Main Results:

• A total of 24 oncologists participated, representing the majority of lung cancer care in Israel.
• 79% of surveyed oncologists routinely perform EGFR testing for all advanced NSCLC patients.
• 60% of participants indicated that they defer first-line therapy until EGFR test results are obtained.

Conclusions:

• EGFR mutation testing is a standard practice among most oncologists in Israel for advanced NSCLC, irrespective of histology.
• The results suggest a common approach of awaiting EGFR test outcomes before initiating systemic treatment in advanced NSCLC.